This is one of the more genuinely surprising reversals in modern urology: the long-standing belief that higher testosterone increases prostate cancer risk has largely been overturned by newer research. Large studies have found no consistent link between high testosterone and prostate cancer risk, and the biological explanation for why turns out to be more interesting than the old assumption.
Where The Fear Originally Came From
The concern traces back to a single, highly influential 1941 study in which researchers found that surgically removing the testes (which drastically lowers testosterone) caused prostate cancer to shrink. This led to decades of the assumption that the reverse must also be true, that higher testosterone would fuel faster prostate cancer growth. That assumption became deeply embedded in medical practice for over 70 years, based largely on that original observation rather than direct testing of the “more testosterone, more cancer” side of the theory.
What Modern Research Actually Found
When researchers finally tested the assumption directly, the evidence didn’t hold up. A large collaborative analysis of 18 prospective studies found no association between naturally occurring serum testosterone levels and prostate cancer risk (Endogenous Hormones and Prostate Cancer Collaborative Group, 2008, Journal of the National Cancer Institute). Separately, studies raising testosterone into the supraphysiological range in healthy men for months found no significant effect on PSA levels or prostate volume, both markers relevant to prostate cancer risk and growth.
The Saturation Model: Why This Makes Biological Sense
The explanation researchers now use is called the saturation model. The idea is that the androgen receptors in prostate tissue that respond to testosterone become fully saturated, meaning maximally activated, at a relatively low testosterone concentration, thought to be somewhere in the range of 150 to 250 ng/dL. Once that saturation point is reached, additional testosterone above it has little to no further stimulating effect on the prostate, because there’s nothing left for it to bind to that isn’t already occupied.
This explains the seemingly contradictory old and new findings at once: severely lowering testosterone below the saturation point (as with castration) does shrink prostate tissue, but raising testosterone above that point, which is where most men’s natural levels already sit, doesn’t drive additional growth.
What This Means For Men Considering Testosterone Therapy
This shift in understanding is part of why testosterone therapy is now being used more confidently, and even studied, in some men with a history of prostate cancer, a practice that would have been considered unthinkable under the old model. That said, this remains an area of active research and individualized medical judgment, and any man with a personal history of prostate cancer considering testosterone therapy should have that conversation directly with his urologist or oncologist.
The Bottom Line
The old fear that high testosterone drives prostate cancer risk has not held up well against modern research, and the saturation model offers a coherent biological explanation for why. This doesn’t mean testosterone and the prostate have no relationship at all, but it does mean the relationship is far more nuanced than “more testosterone equals more cancer risk.”
Frequently Asked Questions
Does testosterone therapy cause prostate cancer?
Current evidence doesn’t support this; the old assumption has been substantially revised based on newer research and the saturation model.
What is the saturation model?
It’s the concept that prostate tissue’s response to testosterone maxes out at a relatively low concentration, so additional testosterone above that point has little further effect.
Can men with a history of prostate cancer take testosterone therapy?
This is being studied and used more often than in the past, but it requires individualized medical judgment and should be discussed directly with a specialist.
Should men with low testosterone worry about developing prostate cancer if they start therapy?
Current research doesn’t support a significant increase in risk from raising testosterone into or slightly above the normal range, though ongoing monitoring is still standard practice.